Abstract:Matrix metalloproteinases (MMPs) are involved in extracellular matrix (ECM) remodeling during embryogenesis, wound healing and tumor development. Aberrant expressions and activation of MMP-2 and MMP-9 are examined as one of the major attributes acquired by tumor neoangiogenic markers including vascular endothelial growth factor (VEGF), basic growth factor (bFGF) and CD105-microvessel density (CD105-MVD) during bladder tumorigenesis. The present study examined the levels of MMP-2, MMP-9, VEGF, bFGF and CD105 to elucidate the relationship among them and associated clinical features in the given cohort of non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) patients. Real time-quantitative PCR was done to examine the gene expressions of MMP-2, MMP-9, VEGF, bFGF and CD105 in 70 NMIBC and 40 MIBC patients. Western blotting and immunohistochemical staining were done to check their immunolevels followed by statistical analyses of their expressions with patients' demographic variables. Scanning electron microscopic (SEM) studies were done in representative non-muscle and muscle invasive tumor specimens to elucidate the tumor vasculature and extent of neoangiogenesis. The study reported an increase in gene expression and immunolevels of MMP-2, MMP-9, VEGF, bFGF and CD105-MVD with tumor stage and tumor grade. Statistical studies examined the relevant associations of their expressions with tumor stage, tumor grade, tumor size, tumor type, and tobacco chewing/smoking history of patients. SEM studies revealed marked differences in the vascular architecture and their spatial distribution indicated by increase in vascular density, vascular sprout proliferation and new blood vessel formation with tumor stage and tumor grade. The discriminatory ability of MMP-2, MMP-9, VEGF, bFGF and CD105-MVD in the diagnosis of NMIBC and MIBC was confirmed by ROC curve analysis which revealed the high sensitivity and low specificity of these markers in a given cohort of patients. Observed positive correlations of angiogenic markers with MMP-2 and MMP-9 in the given cohorts of NMIBC and MIBC patients explain their possible effects on bladder tumorigenesis via vascular angiogenesis. Cox regression (univariate and multivariate) and Kaplan-Meier along with log-rank survival analysis examined the strong expressions of these markers as the predictive indicators of poor survival probability (OS, RFS, PFS, and CSS) in 52 NMIBC and 36 MIBC patients. Significant associations of expressions of MMP-2, MMP-9, VEGF, bFGF and CD105-MVD with clinical variables emphasized their significance in diagnosis of NMIBC and MIBC patients. Survival analysis identified these markers as the independent prognosticators of poor survival of NMIBC and MIBC patients. Nevertheless, multi-center analysis is required to validate their importance in the clinical management of NMIBC and MIBC patients.

BLCA-4 Expression is Related to MMP-9, VEGF, IL-1α and IL-8 in Bladder Cancer but Not to PEDF, TNF-α or Angiogenesis

BLCA1 Expression is Associated with Angiogenesis of Bladder Cancer and is Correlated with Common Pro-Angiogenic Factors

The relationship of expression of p53,p21,Ki-67 and VEGF and bladder cancer stage,grade and prognosis

High Expression Level Of Blca-4 Correlates With Poor Prognosis In Human Bladder Cancer

Bladder Cancer–Specific Nuclear Matrix Proteins-4 May Be a Potential Biomarker for Non-Muscle-Invasive Bladder Cancer Detection

Pigment Epithelium-Derived Factor Expression is Down-Regulated in Bladder Tumors and Correlates with Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9

Expression of Pigment Epithelium-Derived Factor and Tumor Necrosis Factor-Α is Correlated in Bladder Tumor and is Related to Tumor Angiogenesis.

IL4I1: a novel molecular biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer

PDGFRA exhibits potential as an indicator of angiogenesis within the tumor microenvironment and is up-regulated in BLCA

Expression of Pigment Epithelium-derived Factor in Bladder Tumour is Correlated with Interleukin-8 Yet Not with Interleukin-1α

Expression and clinical significance of bladder cancer specific nuclear matrix protein 4 in urine of patients with bladder cancer

MMP28 Expression in Blander Cancer and Its Clinical Significance

EIF4A3 Serves As a Prognostic and Immunosuppressive Microenvironment Factor and Inhibits Cell Apoptosis in Bladder Cancer.

Elevated Expression of Matrix Metalloproteinase-9 is Associated with Bladder Cancer Pathogenesis.

P4HB: A Novel Diagnostic and Prognostic Biomarker for Bladder Carcinoma

Urinary BLCA-4 is Highly Specific for Detection of Bladder Cancer in Chinese Han Population and is Related to Tumour Invasiveness.

The Significance of the Expression of DLL4 and VEGF in Patients with Bladder Transitional Cell Carcinoma

Angiogenesis Related Gene Expression Significantly Associated with the Prognostic Role of an Urothelial Bladder Carcinoma

Matrix Metalloproteinases -2 and -9, Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor and CD105- Micro-Vessel Density are Predictive Markers of Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer Subtypes

Expression of Upa and MMP-9 in Bladder Cancer and Its Relationship with Tumor Angiogenesis

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients